Kamada (NASDAQ:KMDA) Stock, Quote.Headers.trade-ideas

Kamada

Kamada Ltd is a drug-focused, plasma-derived protein therapeutics company. It is involved in the business of developing, producing, and marketing specialty therapeutics using protein purification proprietary technology. Its product portfolio consists of Glassia, Bramitob, Foster, Ixiaro, Factor-IX, and others. The company has two segments namely, Proprietary Products segment and Distribution segment. It derives the majority of its revenue from the Proprietary products segment. The firm categorizes its products in Lung Disease, Vaccines, Haemophilia, Immunoglobulins, Critical care, and Diagnostics.

News

Penny Stocks

Small Cap

Intraday Update

Markets

Movers

Trading Ideas

AAOI

ADXN

AWIN

CFRX

ELIQ

FBYD

FEMY

GROM

MicroCloud Hologram Inc. - Ordinary Shares

HOLO

HUBC

KBNT

KMDA

MBLY

MRTX

MTEK

NNOX

NWLI

PRZO

RPTX

SGLY

SLNG

Spruce Power Holding Corporation Class A Common Stock

SPRU

SVRE

TMPO

TNGX

TSBX

TSLA

TTOO

USEG

VCNX

VIVK

WHLR

WINT

XPEV

ZJYL

Gainers


	ParaZero Technologies Ltd. (NASDAQ: PRZO) shares jumped 106% to $2.3901 after the company announced an Australian regulator approved first commercial drone flights in populated areas and near people using ParaZero safety systems.


Why ParaZero Technologies Shares Are Trading Higher By Over 100%? Here Are Other Stocks Moving In Monday&#39;s Mid-Day Session

AMBO

APGN

BDRX

BIOL

CRMT

CWBR

DRMA

EEIQ

ENVB

EXPR

GTEC

HSAI

HTCR

HYLN

IDAI

IVVD

KINS

NAVB

NFTG

NVTS

OCEA

OCGN

OPRX

ORGO

PANW

PHGE

PLAB

PLCE

PTCT

QBTS

QTEK

iShares FTSE NAREIT Retail Capped Index Fund

SMFL

SPCE

SRPT

UFAB

URBN

USPH

UTRS

VIRI

WOOF

ZURA

Gainers


	Minerva Surgical, Inc.  (NASDAQ: UTRS) shares jumped 209.1% to $0.5622 after the United States Patent and Trademark Office granted the company a patent for certain medical systems and methods.


Why America&#39;s Car-Mart Shares Are Trading Lower By 12%? Here Are Other Stocks Moving In Wednesday&#39;s Mid-Day Session

KIND

RETA

SFWL

VIPS

U.S. stocks traded lower, with the Dow Jones dropping around 200 points on Wednesday. Here are some big stocks recording gains in today’s session.


Abercrombie &amp; Fitch, Urban Outfitters, Photronics And Other Big Stocks Moving Higher On Wednesday

Kamada Ltd

HC Wainwright &amp; Co. analyst Andrew Fein reiterates Kamada (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KMDA#NASDAQ">KMDA</a>) with a Buy and maintains $11 price target.

Price Target

Reiteration

Analyst Ratings

HC Wainwright & Co. Reiterates Buy on Kamada, Maintains $11 Price Target

WIIM

Kamada shares are trading higher after the company issued FY25 guidance above estimates.

<ul>
<li>Provides 2025 Annual Guidance of $178 - $182 Million in Revenue and $38 -&nbsp;$42 Million of Adjusted EBITDA, Representing Year-Over-Year Increase of 13% in Revenues and 19% in Adjusted EBITDA Based on Mid-Point of 2024 Annual Guidance</li>
<li>Expects to Achieve 2024 Guidance of $158 - $162 Million in Revenue and $32 - $35 Million of Adjusted EBITDA; 2024 Year-End Cash of $78 Million</li>
<li>Aiming to Secure New Business Development and M&amp;A Transactions During 2025 that Leverage Overall Financial Strength and Existing Commercial Infrastructure to Accelerate Long-Term Growth</li>
<li>Expansion of Plasma Collection Operations with Opening of a Third Center by End of Q1 2025</li>
<li>Based on Positive Feedback from U.S. FDA, Kamada Plans to Reduce Inhaled AAT Clinical Study Sample Size to Approximately 180 Patients; Interim Futility Analysis Planned by End of 2025</li>
</ul>

Guidance

Kamada Reaffirms 2024 Targets, Unveils 2025 Guidances, Revenue Of $178M-$182M Vs. $171.18M Est. And Adj.EBITDA Of $38M-$42M

Kamada Raises FY24 Adjusted EBITDA Guidance To $32M-$35M, A 12% Increase Of The Midpoint From The Previous Guidance, And Reiterates Revenue Guidance Of $158M-$162M Vs. $160.47M Estimate

Kamada (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KMDA#NASDAQ">KMDA</a>) reported quarterly earnings of $0.18 per share which beat the analyst consensus estimate of $0.07 by 157.14 percent. The company reported quarterly sales of $41.740 million which beat the analyst consensus estimate of $40.923 million by 2.00 percent. This is a 10.03 percent increase over sales of $37.934 million the same period last year.

Earnings

Earnings Beats

Kamada Q3 2024 GAAP EPS $0.18 Beats $0.07 Estimate, Sales $41.740M Beat $40.923M Estimate

ACXP

ADAP

AEMD

AFCG

AFYA

AGRO

AIRJ

ALUR

ALVO

ARCO

ATEX

AYTU

BCDA

BETR

BFRI

BITF

Bakkt Holdings, Inc. Class A Common Stock

BKKT

BNGO

BOXL

BRFS

BWEN

CAAS

CAPR

CREX

CRNT

CSAN

CSCO

CSLR

CSTE

CYBR

DADA

DGII

DMAC

DOLE

DRRX

DTCK

ECOR

EDBL

ENLT

EZPW

FORA

FPAY

FULC

GILT

GLAD

GOEV

GRYP

HIVE

HROW

HYZN

IBTA

ICAD

ICCC

INLX

INVZ

JAGX

JJSF

KBDC

KLIC

KRMD

KULR

LMFA

LOAR

LQDA

LUCD

LVLU

MCRB

MPTI

MRSN

NTWK

NXGL

OMER

OTRK

OWLT

OXBR

PAVM

PCYO

Earnings Scheduled For November 13, 2024

Kamada (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KMDA#NASDAQ">KMDA</a>) is set to give its latest quarterly earnings report on Wednesday, 2024-11-13. Here's what investors need to know before the announcement.
Analysts estimate that Kamada will report an earnings per share (EPS) of $0.07. 
The announcement from Kamada is eagerly anticipated, with investors seeking news of surpassing estimates and favorable guidance for the next quarter.
It's worth noting for new investors that guidance can be a key determinant of stock price movements.
<h3>Performance in Previous Earnings</h3>
During the last quarter, the company reported an EPS beat by $0.02, leading to a 0.75% increase in the share price on the subsequent day.
Here's a look at Kamada's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
<th>Q4 2023</th>
<th>Q3 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.06</td>
<td>0.06</td>
<td>0.05</td>
<td>0.03</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.08</td>
<td>0.04</td>
<td>0.09</td>
<td>0.06</td>
</tr>
<tr>
<td>Price Change %</td>
<td>1.0%</td>
<td>-3.0%</td>
<td>2.0%</td>
<td>1.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2024/1731434822_0.png" alt="eps graph" />
<h3>Kamada Share Price Analysis</h3>
Shares of Kamada were trading at $6.1 as of November 11. Over the last 52-week period, shares are up 31.82%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. 
<a href="https://www.benzinga.com/quote/KMDA/earnings">To track all earnings releases for Kamada visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

What's Next: Kamada's Earnings Preview

Kamada Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KMDA#NASDAQ">KMDA</a>, TASE: KMDA.TA)))), a global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived field, today announced the expansion of its plasma collection operations with the opening of a new plasma collection center in Houston, TX. The new 12,000 square foot center is operated by Kamada's wholly owned subsidiary, Kamada Plasma, and is planned to support over 50 donor beds with an estimated total collection capacity of approximately 50,000 liters annually.
"We are extremely pleased to announce the opening of our new state-of-the-art plasma collection center in Houston," said Amir London, Chief Executive Officer of Kamada. "The opening of this center is an important milestone in Kamada's development and vertical integration, expanding the collection capacity of specialty plasma for our internal use beyond our existing site in Beaumont, TX. The new center in Houston is expected to be one of the largest sites for specialty plasma collection in the U.S. and will also collect normal source plasma to be sold to third parties. We are especially grateful for the skilled and experienced team of plasma collection experts we have hired to lead the development and operations of our new center."
Kamada intends to submit to the FDA a prior approval supplement to Kamada Plasma's existing Biologics License Application (BLA) for the approval of the Houston site, as well as a plasma master file (PMF) to the European Medicines Agency (EMA), during the first half of 2025. The FDA and EMA's regulatory process for obtaining approval for plasma collection centers includes onsite inspection. During the review process, the company is authorized to collect plasma donations at the center. Kamada currently anticipates approval decisions within 9-12 months of submissions.
In addition to the new Houston center, the company has begun construction of its third plasma collection site in San Antonio, TX, which is expected to open during the first half of 2025. Each collection center is expected to contribute annual revenues of $8 million to $10 million in sales of normal source plasma at its full capacity.

Government

Regulations

Kamada Expands US Plasma Operations with Houston Center, Plans FDA Submission

Kamada Reiterates FY24 Revenue Guidance Of $158M - $162M (Est $159.60M) And Adjusted EBITDA Of $28M - $32M

Comments

Kamada

Kamada (KMDA) Forecast

Kamada (NASDAQ:KMDA) Stock, Quote.Headers.trade-ideas

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga